Did you know that two seemingly mundane parliamentary studies could hold the key to Canada's medical future? These under-the-radar investigations might just determine whether Canadians have access to life-saving medicines or become pawns in a profit-driven pharmaceutical game. But here's where it gets controversial: while these studies aim to boost Canada's innovation and preparedness, they might inadvertently prioritize corporate interests over public health. And this is the part most people miss: the fine line between fostering economic growth and ensuring equitable access to healthcare.
In the current parliamentary session, two studies by Standing Committees are quietly unfolding, each with profound implications for medical innovation, pandemic readiness, and the availability of medicines. These studies deserve far more attention than they’re getting, especially because they risk perpetuating a troubling trend: the Canadian government’s tendency to funnel public investment into research and development (R&D) and biomanufacturing primarily to bolster private enterprise rather than to enhance public health.
The first study, conducted by the Standing Committee on Science and Research (SRSR), is deceptively titled Private Sector Investment in Research and Development in Canada. A closer look reveals its true focus: finding ways to accelerate the commercialization of innovations emerging from Canadian universities to strengthen the nation’s economy. In essence, it’s about streamlining the transfer of publicly funded research into private hands. This approach isn’t surprising, given Canada’s growing emphasis on R&D as an economic driver. However, it’s deeply concerning. Publicly funded research at universities has often been handed over to private entities, which then control who can access the resulting innovations—and at what cost. This control can literally mean the difference between life and death when it comes to accessing medicines.
The second study, soon to begin at the Standing Committee on Health (HESA), focuses on Canada’s Pharmaceutical Sovereignty. This issue was thrust into the spotlight during the COVID-19 pandemic, when Canada faced shortages of existing drugs and struggled to access new vaccines. The core problem was Canada’s limited domestic production capacity. Disruptions in global trade and supply chains highlighted the country’s reliance on other nations for both finished medicines and their raw ingredients. It wasn’t until September 2025 that the first doses of a domestically produced COVID-19 vaccine became available.
The pandemic spurred much-needed public investment in domestic biomanufacturing, but much of this funding went toward subsidizing private sector companies, including major multinationals. Handing control to private actors, many of whom are based outside Canada, seems like an odd strategy for achieving pharmaceutical sovereignty. Yet, here we are.
It’s critical that these committees recognize the inherent tension between public health interests and those of the pharmaceutical industry. While their goals sometimes align, they often diverge—especially when it comes to transferring public funds or publicly funded R&D to the private sector. Canada must ensure that public investment prioritizes public benefits, a lesson it has yet to fully embrace.
Take the University of British Columbia, for example, which played a pivotal role in developing key COVID-19 innovations, including the monoclonal antibody treatment bamlanivimab and the lipid nanoparticle technology used in mRNA vaccines. These breakthroughs originated from publicly funded research at a public university. However, after being spun off into private companies, they received additional public funding for development. The ultimate beneficiaries? Private interests. AbCellera, for instance, became Canada’s most valuable biotech company after its record-breaking stock market debut, while Canada paid tens of millions of dollars for the very drug it helped create.
Meanwhile, the lack of access conditions tied to government or university funding for lipid nanoparticle technology left Canada struggling to access mRNA vaccines. Ironically, Canada ended up funding the World Health Organization’s mRNA Tech Transfer Hub in South Africa to reverse-engineer the same technology it had initially supported, after pharmaceutical companies refused to voluntarily share it with low- and middle-income countries.
Relying on private industry to bring products to market inherently disadvantages innovations with high public health impact but low commercial value. Yet, some health researchers argue that public investment in biomanufacturing facilities at universities allows companies to charge premium prices, justifying high upfront costs with long-term healthcare savings. This logic might make sense for private enterprises, but it’s baffling when applied to public funds. Why should taxpayers pay twice—first for the research that lowers treatment costs, and then again to access the fruits of that research at a premium?
This issue extends to essential medicines, many of which are not sold in Canada because they’re deemed insufficiently profitable by the pharmaceutical industry. As a result, patients face significant challenges accessing these life-saving drugs. When globally recognized essential medicines are unavailable domestically, it’s hard to claim that Canada is effectively exercising its pharmaceutical sovereignty.
The same challenge arises with developing new treatments and vaccines. Canada’s reliance on profit-driven companies to bring products to market means that groundbreaking research often struggles to leave the lab. Consider the first effective vaccine against the most common form of Ebola, developed at Canada’s National Microbiology Laboratory in Winnipeg. The convoluted journey of this vaccine—licensed to a company with no prior experience, then sublicensed to another for millions before finally reaching the market at a high price—illustrates the pitfalls of depending on industry.
This pattern repeats itself with other promising vaccine candidates, such as those for Lassa Fever, Marburg virus, and the Sudan form of Ebola virus. Despite originating in Canada, recent funding for these innovations has come from foreign governments like the U.S. and the European Union, not Canada.
The Canadian government has a golden opportunity to shift its focus from subsidizing a lucrative industry to addressing domestic gaps that commercial interests ignore. It must proactively identify these gaps and prioritize health needs over industry desires. Simply having biomanufacturing capacity on Canadian soil isn’t enough; the government must also ensure that this capacity is used effectively. The idle Biologics Manufacturing Centre in Montreal, which has received $17 million annually just to stay operational, is a case in point. The government’s approach of operating it as a contract manufacturer for private interests has clearly failed.
Instead, with a relatively small investment, Canada could meet both domestic and global needs for critical products like monoclonal antibody treatments. This dual approach would not only bolster Canada’s biosecurity stockpiles but also help address global health crises before they reach Canadian shores.
Canada must abandon its failing strategy of appeasing private commercial interests in the hope that it will ensure affordable access to medicines. Let’s hope these two committees reach a similar conclusion: that exercising pharmaceutical sovereignty means prioritizing patients over profits in supporting Canadian R&D and biomanufacturing. But here’s the question: Can Canada truly balance economic growth with public health, or will corporate interests continue to call the shots? What do you think? Share your thoughts in the comments below.
